Bristol John W & Co. Inc. NY Has $150.14 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Bristol John W & Co. Inc. NY lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 288,601 shares of the medical research company's stock after selling 6,536 shares during the quarter. Thermo Fisher Scientific comprises approximately 2.5% of Bristol John W & Co. Inc. NY's investment portfolio, making the stock its 13th biggest holding. Bristol John W & Co. Inc. NY owned 0.08% of Thermo Fisher Scientific worth $150,139,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in TMO. Barrett & Company Inc. bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $28,000. FPC Investment Advisory Inc. acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $28,000. Pillar Financial Advisors LLC bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $29,000. Ameriflex Group Inc. acquired a new position in Thermo Fisher Scientific during the fourth quarter worth $30,000. Finally, Noble Wealth Management PBC bought a new position in Thermo Fisher Scientific in the fourth quarter valued at $35,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Robert W. Baird decreased their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Barclays decreased their price target on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. Scotiabank dropped their price objective on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a research note on Friday, April 25th. Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Wednesday, May 21st. Finally, Wells Fargo & Company dropped their price target on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a research report on Thursday, April 24th. Four analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $607.43.

Thermo Fisher Scientific Stock Performance

TMO stock traded down $1.34 during mid-day trading on Friday, hitting $402.41. 2,521,282 shares of the company were exchanged, compared to its average volume of 1,881,995. Thermo Fisher Scientific Inc. has a 1-year low of $390.50 and a 1-year high of $627.88. The stock has a market capitalization of $151.91 billion, a PE ratio of 24.34, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82. The business has a 50 day simple moving average of $433.07 and a 200-day simple moving average of $501.01. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The business had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. During the same period last year, the firm posted $5.11 EPS. The firm's revenue for the quarter was up .2% compared to the same quarter last year. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.43%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.09%.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the sale, the chief executive officer now directly owns 115,174 shares in the company, valued at approximately $59,506,950.58. The trade was a 7.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president now owns 23,167 shares in the company, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their position. The disclosure for this sale can be found here. Insiders sold 14,075 shares of company stock valued at $7,305,942 in the last quarter. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.